U.S. markets closed
  • S&P Futures

    4,532.75
    -3.75 (-0.08%)
     
  • Dow Futures

    35,527.00
    -30.00 (-0.08%)
     
  • Nasdaq Futures

    15,329.50
    -11.50 (-0.07%)
     
  • Russell 2000 Futures

    2,286.50
    -2.30 (-0.10%)
     
  • Crude Oil

    84.43
    +0.67 (+0.80%)
     
  • Gold

    1,793.30
    -3.00 (-0.17%)
     
  • Silver

    24.38
    -0.07 (-0.28%)
     
  • EUR/USD

    1.1644
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • Vix

    15.43
    +0.42 (+2.80%)
     
  • GBP/USD

    1.3761
    +0.0002 (+0.02%)
     
  • USD/JPY

    113.7020
    +0.2420 (+0.21%)
     
  • BTC-USD

    61,737.31
    +644.97 (+1.06%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,614.58
    -190.27 (-0.66%)
     

Oncocyte to Participate at Needham Virtual Cancer Diagnostics Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

IRVINE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that company management will participate in the 1-on-1 meetings at the upcoming Needham Virtual Cancer Diagnostics 1x1 Conference on Tuesday, August 18, 2020.

About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies.

DetermaRx and DetermaIO are trademarks of Oncocyte Corporation.

Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com

Media Contact
Cait Williamson, Ph.D.
LifeSci Communications, LLC
646-751-4366
cait@lifescicomms.com

Source: Oncocyte Corporation